Pancreas cancer
Conditions
Interventions
High-risk cohort:NA
Cancer precursor lesion cohort:NA
Early, middle and late-stage pancreatic cancer cohort:NA
Sponsors
ShangHai Changhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria for the high-risk cohort; 1. Age >= 18; 2. The subjects voluntarily signed the informed consent form, and the informed consent process complies with GCP regulations; 3. Meet any of the following criteria: 1. Familial pancreatic cancer (diagnosis criteria: >= 2 first-degree/second-degree/third-degree relatives have pancreatic cancer; or 1 first-degree relative has pancreatic cancer and the age at diagnosis is younger than 55 years old); 2. Hereditary pancreatitis (diagnosis criteria: Pancreatitis occurs in early childhood; or >= 2 first-degree/second-degree/third-degree relatives have pancreatitis); 3. History of chronic pancreatitis; 4. New-onset diabetic patients aged >= 50 years with a disease duration of = 18; 2. The subjects voluntarily signed the informed consent form, and the informed consent process complies with GCP regulations; 3. Diagnosed as pancreatic cystic tumors through imaging assessment or pathological examination (including pancreatic intraductal papillary mucinous neoplasm, serous cystadenoma, mucinous cystic tumor, solid pseudopapillary tumor, etc.); Inclusion criteria for the pancreatic cancer cohorts in the early, middle and late stages; 1. Age >= 18; 2. The subjects voluntarily signed the informed consent form, and the informed consent process complies with GCP regulations; 3. Pathologically confirmed pancreatic ductal adenocarcinoma (PDAC);
Exclusion criteria
Exclusion criteria: 1. Patients who have been diagnosed with pancreatic cancer (applicable only to the high-risk population cohort and the precancerous lesion cohort); 2. Pregnant women, lactating women, women with positive pregnancy test results; 3. Patients with severe primary diseases such as cardiovascular and cerebrovascular diseases, liver diseases, kidney diseases, hematopoietic system diseases, or known serious diseases that affect their survival (such as tumors or AIDS), or patients with mental or legal disabilities; 4. The researchers believe that the subjects may have inherent risks or there may be any other factors that interfere with the subjects' performance, such as frequent changes in the working environment, which could lead to loss of follow-up. 5. The subjects were unable to undergo follow-up or were currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion rate;data completeness rate;Follow-up completion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Enrollment time efficiency; | — |
Countries
China
Contacts
Public ContactGang Jin
ShangHai Changhai Hospital
Outcome results
None listed